Drug Information

Drug (ID: DG01833) and It's Reported Resistant Information

• Name: Wnt agonist
• Synonyms: BML-284; Wnt Agonist; 853220-52-7; 2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine; N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; 4-N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; N4-(Benzo[d][1,3]dioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; BML 284; 2-Amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl)pyrimidine; Wnt agonist 1;AMBMP; SCHEMBL430891; Wnt agonist 1(BML-284); Wnt agonist 1 (BML-284); CHEMBL4303671; BML 284;BML284; CHEBI:125559; BCP17186; EX-A2428; HSCI1_000334; NSC762367; ZINC44063027; CCG-208089; CS-5516; NSC-762367; NCGC00386697-01; NCGC00386697-05; AS-56297; HY-19987; C76745; BRD-K42624714-001-01-7; Q27216172; N4-[(2H-1,3-benzodioxol-5-yl)methyl]-6-(3-methoxyphenyl)pyrimidine-2,4-diamine; FW9
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Colorectal cancer [ICD-11: 2B91]; [1]
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Laryngeal cancer [ICD-11: 2C23]; [2]
• Formula: 5
• IsoSMILES: COC1=CC=CC(=C1)C2=CC(=NC(=N2)N)NCC3=CC4=C(C=C3)OCO4
• InChI: InChI=1S/C19H18N4O3/c1-24-14-4-2-3-13(8-14)15-9-18(23-19(20)22-15)21-10-12-5-6-16-17(7-12)26-11-25-16/h2-9H,10-11H2,1H3,(H3,20,21,22,23)
• InChIKey: FABQUVYDAXWUQP-UHFFFAOYSA-N
• PubChem CID: 11210285

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colorectal cancer [ICD-11: 2B91]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: . [1]

• Resistant Disease: Colorectal cancer [ICD-11: 2B91.1]
• Molecule Alteration: .; .
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Wnt/beta-catenin Signalling Pathway; Regulation; N.A.
• In Vitro Model: HCT8 cells; Colon; Homo sapiens (Human); CVCL_2478
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: The results showed that Huaier can regulate autophagy, inhibit the Wnt/-catenin signalling pathway and reverse the drug resistance of OXA-resistant CRC cells.

Laryngeal cancer [ICD-11: 2C23]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: LncRNA neighboring enhancer of FOXA2 (LNCNEF) [2]

• Resistant Disease: Laryngeal carcinoma [ICD-11: 2C23.0]
• Molecule Alteration: Down-regulation; Expression
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: Wnt/Beta-catenin signaling pathway; Inhibition; hsa04310
• In Vitro Model: UM-SCC-17A cells; Larynx; Homo sapiens (Human); CVCL_7724
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Overexpression assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Long non-coding RNA NEF inhibits proliferation and promotes apoptosis of laryngeal squamous cell carcinoma cells by inhibiting Wnt/beta-catenin signaling.

References

• Ref 1: Huaier Regulates Oxaliplatin Resistance in Colorectal Cancer by Regulating Autophagy and Inhibiting the Wnt/beta-catenin Signalling Pathway. Front Biosci (Landmark Ed). 2024 Jan 17;29(1):15.
• Ref 2: Long non-coding RNA NEF inhibits proliferation and promotes apoptosis of laryngeal squamous cell carcinoma cells by inhibiting Wnt/Beta-catenin signalingOncol Lett. 2019 Jun;17(6):4928-4934. doi: 10.3892/ol.2019.10150. Epub 2019 Mar 15.